Physician profile
Jack Ditlove
NPI 1417961186
$1,369.51
in general payments reported to CMS, 2019-2025
17 companies · $28.53 in 2025
The $28.53 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $509 · 2020: $129 · 2021: $212 · 2022: $149 · 2023: $187 · 2024: $156 · 2025: $28.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $371.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $245.28 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $204.07 | 2019-2024 | Breztri, Farxiga |
| Amgen INC. | $174.56 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $128.74 | 2019 | |
| Sanofi-Aventis U.S. LLC | $102.53 | 2020-2022 | |
| Lilly USA, LLC | $84.84 | 2021-2024 | Mounjaro |
| Horizon Therapeutics Plc | $68.19 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $65.70 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.39 | 2021-2023 | Jardiance, Synjardy, Tradjenta |
| Kyowa Kirin, INC. | $58.85 | 2023 | Crysvita |
| Mallinckrodt Hospital Products INC. | $52.31 | 2020-2021 | |
| Opko Pharmaceuticals, LLC | $31.48 | 2019 | |
| Glaxosmithkline, LLC. | $23.28 | 2023 | Shingrix, Arexvy |
| Sanofi Pasteur INC. | $21.06 | 2021 | |
| Merck Sharp & Dohme LLC | $17.83 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.20 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Ditlove listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.